RVP
Retractable Technologies, Inc.0.8200
-0.0124-1.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
24.55MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
8-K
Declares preferred dividends
Retractable Technologies declared dividends of $39,050 to Series II Class B preferred shareholders and $18,561 to Series III holders, covering Q4 2025 at $1.00 per share annually. Payable January 20, 2026 to record holders on January 10. Cash commitment underscores liquidity amid tariff and demand risks.
8-K
Q3 sales steady, Vizient nod
Retractable Technologies posted Q3 net sales of $10.1M, down slightly from $10.3M last year, with operating loss narrowing to $3.7M from $5.1M amid tariff costs of $172K. Nine-month sales hit $28.8M, up from $24.0M, yet operating losses held at $13.5M; U.S. production jumped to 38.3%. Tariffs sting. EasyPoint Blood Collection Tube Holder earned Vizient Innovative Technology designation.
10-Q
Q3 FY2025 results
Retractable Technologies swung to a Q3 profit of $0.01 per diluted share, beating last year's $0.07 loss, while sales dipped 2% y/y to $10.1M yet gross margins soared from near-zero to 16.7% on lower unit volumes but richer product mix favoring VanishPoint syringes over EasyPoint needles. YTD revenue climbed 20% y/y to $28.8M, but operating loss narrowed just 3% to $13.5M (derived) amid $2.3M tariff hits and $1.2M inventory write-downs; net loss of $10.2M reflected $3.2M unrealized investment losses, offset by $1.9M litigation proceeds. Cash fell to $3.4M with $6.5M operating outflow, cushioned by $7M securities sales; long-term debt sits at $0.6M. Tariffs pressure margins.
8-K
Declares preferred stock dividends
Retractable Technologies declared dividends totaling $57,611.25 to Series II and III Class B Convertible Preferred Stock holders, covering July 1 to September 30, 2025, at $1.00 per share annually. Payments hit on October 20, 2025, for record holders as of October 10. This move signals steady cash flow amid manufacturing safety products. Yet liquidity hangs on market access and supplier ties.
8-K
Q2 sales surge amid tariffs
Retractable Technologies reported Q2 2025 net sales of $10.4 million, up from $6.0 million last year, driven by 109.2% higher unit sales, yet operating losses narrowed to $5.1 million from $5.8 million amid tariff pressures. For the first half, sales reached $18.7 million versus $13.6 million prior, but operating losses widened to $9.8 million from $8.7 million, with $2.1 million spent on tariffs despite shifting 38% of production to the U.S. from 9%. Tariffs will materially hike future costs. A $1.9 million litigation settlement provided relief, while a $5.6 million unrealized investment loss stung.
IPO
Website
Employees
Sector
Industry
AVTR
Avantor, Inc.
11.20-0.08
BAX
Baxter International Inc.
19.05-0.48
IRMD
iRadimed Corporation
96.87-0.15
MHUA
Meihua International Medical Te
7.61-6.41
RMD
ResMed Inc.
247.34-5.73
RSCF
Reflect Scientific, Inc.
0.05+0.00
RXST
RxSight, Inc.
12.76+0.24
STSS
Sharps Technology Inc.
2.22+0.00
VTAK
Catheter Precision, Inc.
2.19-0.04
WST
West Pharmaceutical Services, I
266.44-5.42